Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Yondelis (trabectedin) is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• The pooled median overall survival (mOS) for patients with metastatic synovial sarcoma (mSS) treated with either pazopanib or trabectedin was 10.4 months, with similar outcomes across agents (pazopanib: 10.3 months; trabectedin: 10.4 months) and settings (clinical trials: 10.8 months; real-world: 9.9 months).
• The overall response rate (ORR) was 14.7%, with pazopanib demonstrating a higher ORR (18.9%) compared to trabectedin (12.3%). ORR was also higher in real-world settings (17.7%) than in clinical trials (9.5%).
• No specific subgroups within the metastatic synovial sarcoma population were identified as having differential effectiveness outcomes.
• Trabectedin has an estimated incidence of cardiac toxicity at 3.4% in patients, with a noted increased risk of heart failure, particularly in those with prior or concurrent anthracycline exposure.
• There is no specific safety information available for pazopanib in the reviewed studies, making direct safety comparisons between trabectedin and pazopanib impossible based on the provided data.